Patients Often Lose in the Battle between Pharma and PBMs

Brooke Loving doesn’t take the medication that would keep her von Willebrand disease under control. Because of the cost, she has made the decision to focus on treating her children instead. Brooke and three of her eight children have been diagnosed with von Willebrand disease, which is a bleeding disorder that is characterized by low levels of von Willebrand factor, a protein that helps blood clot.

Two of Brooke’s children take Humate-P, a von Willebrand factor/factor VIII replacement therapy. It’s expensive but CSL Behring, Humate-P’s manufacturer, offers copay assistance of $10,000 a year.

To read more, click here.